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The Tax I trans-activator protein of the human T-cell leukemia virus I (HTLV-I) enhances viral gene expression through
enhancer sequences in the viral LTR. These sequences consist of three imperfect 21-bp repeats (TRE-1) and a region
between the promoter central and promoter proximal TRE-1 (known as TRE-2). We have previously described the in vivo
footprint of the HTLV-I TRE-1s and TRE-2 in two HTLV-I-infected cell lines, MT-2 and MT-4. MT-2 is a high-level producer of
virus and shows significant DNA–protein interactions within the TRE-1s and TRE-2. In contrast, the proviral DNA in MT-4 cells
is heavily methylated and produces no detectable virus. In this report, we describe the footprints of the TRE-1s and TRE-2
in MT-4 cells that were induced to express high levels of viral proteins by treatment with 5-azacytidine, a potent inhibitor of
methylation. The footprints of the TRE-1s in 5-azacytidine-treated MT-4 cells were virtually identical to those observed in
MT-2 cells. In contrast, the footprints within the TRE-2 region of 5-azacytidine-treated MT-4 cells did not resemble those in
either MT-2 or MT-4 cells. © 2001 Academic Press
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The human T-cell leukemia virus I (HTLV-I) is the eti-
ological agent of an aggressive leukemia known as adult
T-cell leukemia (Poiesz et al., 1980; Yoshida et al., 1982)
and a neurological disorder known as HTLV-I-associated
myelopathy/tropical spastic paraperesis (Gessain et al.,
1985; Osame et al., 1986). The Tax I protein of HTLV-I is
a virus-coded trans-activator that enhances viral gene
expression through target sequences in the U3 region of
the viral long terminal repeat (LTR) (Fujisawa et al., 1985,
1986; Sodroski et al., 1984). It is believed that Tax I
enhances transcription by interacting with cellular tran-
scription factors that specifically bind the target DNA
sequences in the viral LTR. These sequences consist of
three imperfect 21-bp repeats, known as TRE-1s, and a
region between the promoter central and promoter prox-
imal TRE-1, known as TRE-2 (Fig. 1) (Brady et al., 1987;
Fujisawa et al., 1986; Marriott et al., 1989; Miwa et al.,
1984; Paskalis et al., 1986; Rosen et al., 1985, 1987;
Shimotohno et al., 1986). MT-4 and MT-2 are human
T-cell lines that were generated by cocultivation of cord
blood lymphocytes with cells from leukemic HTLV-I-in-
fected patients (Miyoshi et al., 1981). MT-4 cells produce
low/undetectable levels of HTLV-I, while MT-2 cells are
high-level producers of the virus (Koyanagi et al., 1984).
We previously used in vivo footprinting to show that
HTLV-I LTRs in MT-4 cells do not show any appreciable
1 To whom correspondence and reprint requests should be ad-
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207DNA–protein interactions within the TRE-1s and only
weak interactions within the TRE-2 (Datta et al., 2000). In
contrast, the MT-2 cells show significant DNA–protein
interactions within the TRE-1s and the TRE-2 (Datta et al.,
2000).
Other investigators have shown that the low level of
viral gene expression in MT-4 cells is due to extensive
methylation of the proviral DNA (Saggioro et al., 1990).
Moreover, treatment of these cells with 5-azacytidine, a
potent inhibitor of DNA methylation, results in induction
of viral expression (Saggioro et al., 1990). In this report,
we have exploited the inducibility of HTLV-I expression in
MT-4 cells to further investigate the effects of Tax I
expression on DNA–protein interactions within the
HTLV-I LTR. We performed genomic in vivo footprinting of
the HTLV-I LTRs in MT-4 cells after treatment with 5-aza-
cytidine. The results indicated that the 5-azacytidine in-
duction was accompanied by an increase in Tax I activity
and also an increase in proteins bound to the HTLV-I
enhancer sequences.
RESULTS AND DISCUSSION
We first investigated the effect of 5-azacytidine on Tax
I expression. It has been reported that maximal viral
gene expression in MT-4 cells is seen 12 days after
treatment with 5-azacytidine (Saggioro et al., 1990). In
initial experiments, we confirmed induction of HTLV-I
expression upon 5-azacytidine treatment of MT-4 cells,
but in our experiments, maximal levels of Tax I RNA and
protein were observed 6 days after treatment with 5 mM0042-6822/01 $35.00
Copyright © 2001 by Academic Press
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208 DATTA, KOTHARI, AND FAN5-azacytidine (data not shown). We tested if the increase
in the levels of Tax I RNA and protein also were reflected
in an increase in the levels of biologically active Tax I in
a transient transfection assay of 5-azacytidine-treated
MT-2 and MT-4 cells using a reporter plasmid containing
the secreted alkaline phosphatase gene under the con-
trol of the HTLV-I LTR (Fig. 2). MT-2 cells did not show any
change in their ability to support high-level expression of
the HTLV-I LTR after treatment with 5-azacytidine (Fig.
2A). In contrast, MT-4 cells showed an approximately
fourfold increase in their ability to express the HTLV-I
LTR after treatment with 5-azacytidine (Fig. 2B), indicative
of higher levels of biologically active Tax I.
While the most likely explanation for the results of Fig.
2 was activation of the resident HTLV-I proviruses in the
MT-4 cells by 5-azacytidine treatment, it was also possi-
FIG. 1. Schematic of the HTLV-1 LTR. 11 denotes the start site of tra
FIG. 2. Tax I activity in 5-azacytidine-treated MT-2 and MT-4 cells.
Untreated or 5-azacytidine-treated MT-2 or MT-4 cells were transfected
with a reporter plasmid that had the secreted alkaline phosphatase
(SEAP) gene under the control of the HTLV-I LTR as described under
Materials and Methods. SEAP activity was determined 72 h posttrans-
fection. The columns represent values that were corrected for trans-
fection efficiency. Error bars indicate the standard error. (A) Relative Tax
I activity in untreated MT-2 cells and 5-azacytidine-treated cells. (B)
Relative Tax I activity in untreated, 5-azacytidine (AZA)-treated, AZT-
treated, and 5-azacytidine plus AZT-treated MT-4 cells (see text for
details).ble that the increase in Tax I activity was due to reinfec-
tion of the MT-4 cells by induced HTLV-I virions, followed
by integration into more transcriptionally active parts of
the genome. To address this possibility, we also tested
reporter activity in MT-4 cells after treatment with 5-aza-
cytidine in the presence of AZT at concentrations that
would block new rounds of viral infection (Macchi et al.,
1997) (Fig. 2B). MT-4 cells showed essentially the same
5-azacytidine induction of the HTLV-I LTR activity in the
presence or absence of AZT (Fig. 2B). Treatment with
AZT alone resulted in an approximately 50% drop in the
reporter activity in MT-4 cells. This indicated that the
5-azacytidine treatment did not result in substantial new
rounds of viral infection during the times studied here.
These data collectively demonstrated that treatment of
MT-4 cells with 5-azacytidine resulted in an increase in
the levels of Tax I RNA (not shown) and biologically
active Tax I protein. Further, they also indicated that
incorporation of 5-azacytidine into the HTLV-I LTR did not
affect its ability to respond to Tax I. We next used 5-aza-
cytidine-treated MT-4 cells to investigate the effect of
increasing levels of active Tax I on the in vivo pattern of
DNA–protein interactions for the HTLV-I LTR.
We have previously described in vivo footprints of the
HTLV-I LTR in MT-2 and MT-4 cells obtained by using in
vivo dimethyl sulfate (DMS) methylation followed by liga-
tion-mediated PCR (LMPCR) (Datta et al., 2000). In this
technique, live cells are exposed to DMS at concentra-
tions that will partially methylate accessible guanine
residues within the genome. DNA is then extracted from
these cells and cleaved at methylated guanine residues
with piperidine; the cleavage pattern of the DNA within
the HTLV-I LTR is analyzed by ligation-mediated PCR
using nested LTR-specific primers. This technique gen-
erates a G-ladder of the sequence of interest; in vivo
protections or hypersensitivities to DMS methylation of
these guanine residues are deduced by comparing the
relative methylation of a guanine residue in in vivo DMS-
treated DNA to DNA that has been exposed to DMS after
being extracted from the same cells (in vitro). Using this
technique we have shown that the CREs in all three
TRE-1s in MT-2 cells are occupied to varying degrees,
with the promoter proximal TRE-1 showing the strongest
interactions (as judged by the degree of protection or
tion. The relative positions of the TRE-1s and the TRE-2 are shown.hypersensitivity) (Datta et al., 2000). In contrast, MT-4
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209IN VIVO HTLV-I FOOTPRINTINGcells showed no evidence of protein binding within the
TRE-1s and only weak interactions within the TRE-2
(Datta et al., 2000).
Before performing in vivo DMS footprinting on 5-aza-
cytidine-treated MT-4 cells, we first investigated whether
the drug had any general effects on the signal obtained
by in vitro DMS footprinting and LMPCR (Fig. 3). The
signal from a standard LMPCR reaction on in vitro DMS-
treated and piperidine-cleaved DNA from MT-4 and MT-2
cells grown in the absence of 5-azacytidine is shown in
Fig. 3 (lane c, MT-4; lane f, MT-2). The LMPCR signal from
the same DNA samples after cleavage with piperidine
but without DMS treatment is shown in lane b (MT-4) and
lane e (MT-2). Piperidine cleavage without prior DMS
treatment produced a low-level signal at all nucleotides;
this is probably reflective of a low-level degradation of
the DNA templates and the sensitivity of the LMPCR
assay. Surprisingly, piperidine cleavage without prior
DMS treatment on DNA from 5-azacytidine-treated MT-4
cells produced strong bands that corresponded to the
cytosine residues in the sequence (lane a). This sug-
gests that piperidine can cleave DNA at 5-azacytidine
residues. For reference, the signal from a standard
LMPCR reaction on in vitro DMS-treated and piperidine-
FIG. 3. LMPCR on in vitro DNA from MT-4 and MT-2 cells. High-
olecular-weight DNA from MT-4 and MT-2 cells that had been grown
n medium with or without 5-azacytidine (AZA) was used for LMPCR
nalysis as described under Materials and Methods using oligonucle-
tides that would generate a footprint of the lower strand of the
romoter proximal TRE-1. The guanine residues in the TRE-1 are num-
ered and the entire sequence of the TRE-1 is shown. Lane a: in vitro
iperidine-cleaved DNA from MT-4 cells grown in the presence of
zacytidine. Lane b: in vitro piperidine cleaved DNA from MT-4 cells
rown in the absence of azacytidine. Lane c: in vitro DMS-treated and
iperidine-cleaved DNA from MT-4 cells grown in the absence of
zacytidine. Lane d: in vitro DMS-treated and piperidine-cleaved DNA
rom MT-2 cells grown in the presence of azacytidine. Lane e: in vitro
iperidine-cleaved DNA from MT-2 cells grown in the absence of
zacytidine. Lane f: in vitro DMS-treated and piperidine-cleaved DNA
rom MT-2 cells grown in the absence of azacytidine.cleaved DNA from MT-2 cells grown in the presence of M5-azacytidine is shown in lane d. DNA from 5-azacyti-
dine-treated MT-2 cells also showed pronounced bands
at C residues in addition to the expected bands at G
(guanine) residues upon LMPCR compared to DNA from
cells not treated with 5-azacytidine (lane d).
We also investigated the effects of 5-azacytidine incor-
poration on the in vivo DMS-footprinting/LMPCR proce-
ure. In order to do this we compared the results of in
ivo footprinting of MT-2 cells grown in 5-azacytidine to
ur previously reported footprints for MT-2 cells. The
esults of such an analysis on the lower strand of the
romoter central TRE-1 are shown in Fig. 4A. The bands
orresponding to C residues in the TRE-1 have been
arked with asterisks. Arrows pointing toward the gel
esignate hypersensitivities (as in Fig. 5) and arrows
ointing away indicate protections. The footprint ob-
erved for the promoter-central TRE-1 in 5-azacytidine-
reated MT-2 cells is compared to our previously re-
orted footprint for the same TRE-1 in untreated MT-2
ells (Datta et al., 2000) in Fig. 4B. In parallel with our
observation that there was no change in the reporter
activity of MT-2 cells grown in the presence of 5-azacy-
tidine (Datta et al., 2000), there was also no change in the
ootprint from that observed previously. We also did not
FIG. 4. Effects of 5-azacytidine incorporation on in vivo DMS foot-
rinting and LMPCR. (A) DNA from in vivo DMS-treated MT-2 cells that
as grown in medium containing 5-azacytidine (AZA) was subjected to
standard LMPCR reaction using oligonucleotides that would analyze
he lower strand of the promoter central TRE-1 as described under
aterials and Methods. The G residues in the sequence are num-
ered; asterisks denote the C residues. Arrows pointing away from the
el denote protections; large arrowheads indicate major protections.
B) Comparison of the footprint of the lower strand of the promoter
entral TRE-1 in MT-2 (from Datta et al., 2000) and 5-azacytidine-treated
T-2 cells. P, protected residue; P, strong protection.
210 DATTA, KOTHARI, AND FANobserve any change in the footprints of the other two
TRE-1s and the TRE-2 from their patterns in untreated
cells (not shown). These data suggest that besides that
DNA could be cleaved by piperidine at 5-azacytidine
residues, there were no fundamental changes in the
footprint when 5-azacytidine was incorporated into the
DNA.
FIG. 5. In vivo DMS footprinting of the lower strand of the TRE-1s in
promoter central, and (C) promoter proximal TRE-1 are shown. In vivo
are numbered. Arrows pointing away from the gel indicate protected res
arrowheads indicate major protected or hypersensitive residues. C resi
along with the footprints previously reported for untreated MT-2 and MT
to Fig. 4B are used; H, hypersensitivity.The in vivo footprints of the lower strand of the TRE-1sin 5-azacytidine-treated MT-4 cells are shown in Fig. 5. In
this report, we concentrated on the lower strand of the
LTR since it is very G-rich and, therefore, more informa-
tive than the upper strand in this assay. The guanine
residues in each TRE-1 have been numbered. The inten-
sity of each guanine residue in the in vivo sample was
compared to the intensity of the cognate guanine in the
ytidine-treated MT-4 cells. The footprints of the (A) promoter distal, (B)
MPCR was performed as in Fig. 4A. The G residues in the sequences
arrows pointing toward the gel indicate hypersensitive residues. Large
e denoted by asterisks. Footprints of the three TRE-1s are summarized
(Datta et al., 2000). The same conventions as described in the legend5-azac
DMS L
idues;
dues ar
-4 cellsin vitro sample by phosphorimager quantification. The
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211IN VIVO HTLV-I FOOTPRINTINGfootprints of the TRE-1s in 5-azacytidine-treated MT-4
cells are also summarized, along with the patterns we
previously reported for MT-2 cells and MT-4 cells (Datta
et al., 2000) in the absence of 5-azacytidine in Fig. 5.
Most importantly, in 5-azacytidine-treated MT-4 cells,
footprints were evident in each of the TRE-1s, in contrast
to the absence of footprints over these sequences in
MT-4 cells grown in regular medium. Moreover, MT-4
cells treated with 5-azacytidine showed very similar foot-
prints to those of MT-2 cells. All 17 of 26 total guanine
residues in the three TRE-1s that were protected or
hypersensitive in MT-2 cells were also correspondingly
protected or hypersensitive in 5-azacytidine-treated MT-4
cells. The only differences observed between the foot-
prints were a protection of the G1 and G2 guanines in the
promoter distal TRE-1 and a protection of the G7 guanine
in the promoter central TRE-1 that had not been ob-
served in MT-2 cells (Datta et al., 2000). These data
suggest that the footprints in MT-2 and 5-azacytidine-
treated MT-4 cells are very likely caused by the same (or
similar) protein complex(es). In vitro, the TRE-1s can be
bound by several members of the CREB-ATF family of
transcription factors or also jun family transcription fac-
tors (Jeang et al., 1988; Nyborg et al., 1990; Tan et al.,
989; Tsujimoto et al., 1991; Yin and Gaynor, 1996a,b;
oshimura et al., 1990; Zhao and Giam, 1992). Indeed, it
as been shown that in vitro, Tax I enhances the dimer-
FIG. 6. In vivo DMS footprinting of the lower strand of the TRE-2 in 5
5. The predicted binding sites for different transcription factors are in
previously reported for untreated MT-2 and MT-4 cells (Datta et al., 20zation and DNA binding of both CREB-ATF and Jun mroteins (Wagner and Green, 1993). Thus, the observa-
ion that identical footprints are observed in both cell
ines suggests that Tax I expression in vivo results in
referential loading of the same transcription factors
nto the TRE-1s in MT-2 and 5-azacytidine-treated MT-4
ells, since it seems unlikely that all the proteins that can
otentially bind the TRE-1s would yield the same in vivo
ootprint.
Lastly, we analyzed the lower strand of the TRE-2 in
-azacytidine-treated MT-4 cells (Fig. 6). MT-2 and MT-4
oth show evidence of DNA-protein interactions within
he TRE-2 region (Datta et al., 2000). However, the foot-
rints are different, suggesting that a different protein(s)
s bound to the sequences in the two cell lines. MT-2
ells show very strong protections spanning several pu-
ative factor-binding sites in the TRE-2, while MT-4 cells
how two hypersensitivities within this region and much
ess extensive protections (Datta et al., 2000). It was
nteresting that in 5-azacytidine-treated MT-4 cells, the
RE-2 footprint shifted to a pattern that resembled nei-
her MT-2 nor MT-4 cells. The two hypersensitive gua-
ines observed in MT-4 cells at G7 and G11 (Datta et al.,
000) were also present in 5-azacytidine-treated MT-4
ells; also, G11 was strongly hypersensitive only in
-azacytidine-treated cells. In contrast, MT-2 cells are
rotected at the G7 residue and hypersensitive at the
11 residue. The AP-2/PEA-3 binding sites also showed
tidine-treated MT-4 cells. In vivo footprinting was performed as in Fig.
. The footprint of the TRE-2 is summarized along with the footprints
e same conventions as described in the legend to Fig. 5 are used.-azacy
dicated
00). Thore extensive protections in 5-azacytidine-treated MT-4
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212 DATTA, KOTHARI, AND FANcells. All of the G residues in this region (G1–G6) were
protected, and G6 and G2–G4 were strongly protected.
MT-2 cells, however, were hypersensitive at G4. Also,
three guanine residues (G7–G9) spanning the 59 end of
he predicted NF-kB binding site showed indications of
DNA–protein interactions. The pattern in this region re-
sembled MT-2, except that G7, which is protected in
MT-2 cells, remained strongly hypersensitive in 5-azacy-
tidine-treated MT-4 cells. The remaining G residues in
the NF-kB region (G10–G13) showed an MT-2-like pat-
tern, although the relative intensities of the bands were
different. The footprints of the TRE-2 are also summa-
rized in Fig. 6 along with the patterns we previously
reported for MT-2 and MT-4 cells (Datta et al., 2000).
These data indicated that unlike the TRE-1s, the TRE-2
displayed a footprint that was unlike MT-2 or MT-4; in-
stead, the footprint observed was a hybrid between the
two cell lines.
It has been reported that the TRE-2, in conjunction with
least one TRE-1, is capable of imparting Tax I respon-
siveness to the HTLV-I LTR in vitro (Numata et al., 1991).
This has led to the suggestion that the TRE-2 is a target
of Tax I in the activation of the HTLV-I LTR in vivo (Numata
et al., 1991). However, the absence of a complete shift of
the TRE-2 footprint to a MT-2 like pattern raises the
possibility that the TRE-2 sequences may not be essen-
tial for Tax I-mediated activation of the HTLV-I LTR in vivo,
at least in MT-4 cells induced by 5-azacytidine. This is
even more striking given that the TRE-1 footprints were
completely converted to a MT-2-like footprint. One pos-
sible explanation for the difference between the conclu-
sions of the previous studies and those of ours could be
that our in vivo footprinting studied integrated proviral
DNA in the context of chromatin, while the previous
studies used transient transfection assays in which the
transcribed DNA is not in native chromatin.
One potential criticism of our in vivo footprinting ex-
periments could be that only a subset of the HTLV-I
proviruses were transcribed in the 5-azacytidine-treated
MT-4 cells; thus, the TRE-2 footprint might reflect inactive
rather than active proviruses. However, both MT-2 and
MT-4 cells contain approximately seven proviruses each
(Cavrois et al., 1995; Kobayashi et al., 1984), at least one
of which is full length. In addition, six of seven defective
proviruses in MT-2 cells are capable of Tax I expression
(Kobayashi et al., 1984). Since 5-azacytidine-treated MT-4
cells express similar levels of Tax I RNA and protein
compared to MT-2 cells (unpublished observations), it
seems likely that most of the proviruses in these two
cells are being transcribed. Also, the appearance of
protections and hypersensitive sites in the TRE-1s after
5-azacytidine induction of MT-4 cells indicated that the
chromatin configuration of a substantial number of the
HTLV-I proviruses had changed. It should also be noted
that the analysis of the lower strand (Fig. 5) combined
signals from both the upstream and downstream LTRs.Thus, in the case of the strongest protections (e.g., the
central G residues in the TRE-1s), this might indicate
factor binding in both LTRs after 5-azacytidine treatment.
Taken together, these facts support the argument that
the dissimilarities in the TRE-2 footprints between 5-aza-
cytidine-treated MT-4 and MT-2 or untreated MT-4 cells
are probably significant. However, considering that the
MT-2 cells show strong DNA–protein interactions within
the TRE-2 (Datta et al., 2000), it is possible that the TRE-2
may be involved in Tax I-mediated activation of the
HTLV-I LTR only upon sustained expression of Tax I. We
were unable to test this possibility because 5-azacytidine
is toxic and the cells cannot be maintained in medium
containing the drug for extended periods.
In summary, we have demonstrated in this report that
treatment of MT-4 cells with 5-azacytidine results in ac-
tivation of viral expression, an increase in biologically
active Tax I, and a change in DNA–protein interactions
within the HTLV-I LTR in vivo. The footprints within the
TRE-1s are strikingly similar to those seen in highly
expressing MT-2 cells. In contrast, the footprints within
the TRE-2 of 5-azacytidine-treated MT-4 cells did not
resemble those of MT-2 or MT-4 cells. Instead, they
resembled a hybrid between MT-2 and MT-4 cells at the
predicted AP-2 and NF-kB binding sites. These results
re consistent with our previous suggestion that the in
ivo footprints seen within the TRE-1s reflect Tax I-de-
endent loading of transcription factors. Further, they
aise the possibility that the TRE-2 may not be essential
or 5-azacytidine-induced Tax I-mediated activation of the
TLV-I LTR in vivo in the context of chromatin.
MATERIALS AND METHODS
ell lines
In vivo footprinting was performed on the MT-4 and
T-2 cell lines (Miyoshi et al., 1981), both human T-cell
ell lines isolated from cord blood lymphocytes that were
ocultured with leukemic cells from patients with HTLV-
-associated adult T-cell leukemia. The NIH AIDS Re-
gent Program provided the MT-4 and MT-2 cells. The
ell lines were cultured in RPMI 1640 supplemented with
0% fetal bovine serum. For 5-azacytidine treatment,
T-4 cells were grown in medium containing 5 mM
5-azacytidine for 6 days before DMS treatment.
Transfections and reporter assays
MT-2 or MT-4 cells were cotransfected with pHTLV-I
LTR-SEAP (a reporter plasmid containing the HTLV-I LTR
driving the secreted alkaline phosphatase reporter gene)
and pRL-null (a promoter-less Renilla luciferase reporter
plasmid; Promega) as described previously (Datta et al.,
2000). Details on the construction of pHTLV-I LTR-SEAP
will be provided upon request. The medium was sam-
pled for SEAP activity 72 h posttransfection. SEAP activity
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cent reporter gene assay kit (Tropix, Inc.) according to
the manufacturer’s instructions. For treatment with 5-aza-
cytidine or 5-azacytidine plus AZT, MT-4 cells were
grown in the presence of 5 mM 5-azacytidine or 5 mM
-azacytidine plus 0.02 mM AZT for 3 days. The cells
ere then transfected with pHTLV-I LTR SEAP and pRL-
ull and the medium was sampled for SEAP activity 3
ays posttransfection.
n vivo footprinting and ligation-mediated PCR
In vivo footprinting visualized by LMPCR was per-
ormed essentially as described by Mueller and Wold
1989), with minor modifications. Detailed descriptions of
he procedure and the specific oligonucleotides used for
TLV-I are described in Datta et al. (2000). Briefly, expo-
nentially growing cells were treated with DMS under
conditions that resulted in partial methylation of guanine
residues. High-molecular-weight DNA was then ex-
tracted from the cells and cleaved to completion with
piperidine (at methylated G residues). The cleaved DNA
was then subjected to a series of nested PCR-based
primer extensions and amplifications using primers spe-
cific for the HTLV-I LTR. The final PCR amplification was
performed using a 32P-labeled HTLV-I LTR-specific
primer, and the reaction was separated on a sequencing
gel and exposed to film or a storage phosphor screen for
quantitative analysis. As a control, high-molecular-
weight DNA was extracted from the cells, subjected to
DMS treatment in vitro, and then processed in parallel
with the in vivo samples.
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